Hepatitis C treatment completion rates in routine clinical care. - Wikidata - awgldk - TriplyDB

Hepatitis C treatment completion rates in routine clinical care.

Hepatitis C treatment completion rates in routine clinical care.

http://www.wikidata.org/entity/Q35093134

about

Barriers to hepatitis C treatment Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection.HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.High rates of early treatment discontinuation in hepatitis C-infected US veterans.A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study.Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment.The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES.Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration The high comorbidity burden of the hepatitis C virus infected population in the United States.Rate, delay and predictors of hepatitis C treatment in British Columbia Anemia management in the era of triple combination therapy for chronic HCV.Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health/substance abuse issues.Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease.Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response.A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans Factors associated with completion of a behavioral intervention for caregivers of urban children with asthma.Liver fibrosis progression in hepatitis C virus infection after seroconversion The epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods.Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus Coinfection.Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs.Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.Association between interferon use and reduced metabolic and vascular complications among patients with hepatitis C.The Rate of Referral of Hepatitis Virus Carriers to Hepatologists and the Factors Contributing to Referral.Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.Treatment of chronic hepatitis C in Croatian war veterans: experiences from Croatian reference center for viral hepatitis.All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia.

P2860

Q27012664-E1770D3C-5618-4528-80FA-E4BFA7493B0B Q30151392-9666140E-D789-4EEB-8EA5-AA3814425AC9 Q30224806-E509E3B5-10CF-4339-85C2-526CCF875788 Q31012317-38294384-72F7-4E18-8493-4161E87925B7 Q33419423-53B95026-53C6-4372-98B0-B2EF3A21F4CD Q33574602-4EFA24B2-FC46-4F81-8A92-B0BE996B3F6A Q34322384-8175DFBC-4F68-4AFF-B3C4-0FB441934F5C Q34677310-21962C42-7162-4F94-AF80-E946BA5FED75 Q35184927-72BA8F58-875B-48EA-A982-9A30735834C4 Q35249642-7DB99D93-4EDD-4F8B-A3FC-38B613AD03F9 Q35838417-E4BBC0BE-1589-4069-B7C2-136AF2029112 Q35856799-AC638164-62A5-4341-9678-8D4373EBC5C1 Q35864236-6C792EE6-92B3-4B42-B731-A52D89A035BB Q35927970-6BF416D5-5F20-48F4-B1F6-A2FC7E094A79 Q36082161-0633AED2-07CB-42D1-8914-7793BEDD2AAB Q36496953-ED5E248D-055C-4BE7-8735-A4F19281DBA6 Q36531731-B8CAC2FC-E2F5-4DF2-B87D-C8D9B73C3184 Q36933104-489FD97B-4739-41DB-ADD4-EBA6A6250AE4 Q36942884-5788656D-0EA5-474A-8E0A-07D2118902E6 Q36955116-7890F63C-ACC2-4D2B-97C1-51D5D459FD3F Q37035655-E089949B-59D7-44A0-9166-EC47BD98EFD4 Q37172069-04AE39F7-0040-49FA-AC38-B08871803E5A Q37244507-8ACC1B51-E0A7-402B-9B40-185F3C2276EC Q37440320-8C80F255-CA0E-49E7-B98E-08F77878F9E6 Q37731286-1FC0794D-9851-4E18-81F8-75B26AF0E339 Q38323723-1FC03E39-D861-4932-A6C1-3F928AC145B3 Q38933599-86BDC8D6-1D98-4A20-B2B0-22D33BB267E5 Q39146830-4FEC10E4-63D6-4962-B796-15BE54F1E9AD Q40097439-D40F3EE7-F4F7-4064-80F1-3E78FFAFB990 Q40428996-043113BC-6ECC-4326-A374-031A8E52B8BB Q40489570-78F3FD90-B4E2-4138-901B-2CFCA7EC5BC4 Q40891023-BD0150AE-6CA3-48D9-89FD-724708DFAA48 Q41486392-5CE8D2C1-12AD-46B3-95A1-136C34E298F7 Q42090512-01856F6A-C490-417C-AEFA-6709F6DD8802 Q42238837-2A374073-A4FE-4847-AD8F-55EE1A5227EB Q45306504-3F96F15C-DDF6-4A15-9FD2-F92511DBA007

P2860

Hepatitis C treatment completion rates in routine clinical care.

http://www.wikidata.org/entity/Q35093134

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hepatitis C treatment completion rates in routine clinical care.

@ast

Hepatitis C treatment completion rates in routine clinical care.

@en

type

label

Hepatitis C treatment completion rates in routine clinical care.

@ast

Hepatitis C treatment completion rates in routine clinical care.

@en

prefLabel

Hepatitis C treatment completion rates in routine clinical care.

@ast

Hepatitis C treatment completion rates in routine clinical care.

@en

P1433

Q35093134-A683B76B-E651-4DF1-BDED-BB80DA736A88

P1476

Q35093134-A9E09685-EB1B-4DD7-8F63-ACFE846BD67A

P2093

Q35093134-07602B93-13F8-416C-A1E3-9801D4EF2B8B

Q35093134-0E8903F1-8AA4-446A-AE4E-E6F52AFF93BA

Q35093134-8F298B09-CEBB-4A27-85BD-C98308531521

Q35093134-B2F8B18E-0662-43F5-91D4-738BAB85657B

P2860

Q35093134-0B5519BE-BA0B-46E0-A410-D0BA860BD1A5

Q35093134-1263982B-4F57-44A0-9DDB-695B21C637E7

Q35093134-201A0FB4-9D67-4B28-9BA2-ABED0648EE00

Q35093134-24312A4E-C047-447F-B705-FF1EB8A033A7

Q35093134-25D56B68-6E70-431D-ABCD-B6980E6B1CDC

Q35093134-2A38F7B8-F9D4-4A32-8668-6D4E6B376C4B

Q35093134-2C1E9EA1-52EC-4833-9483-54AC5906952F

Q35093134-32661A56-DC9F-4419-8FDA-EC0C9EEDF36D

Q35093134-340E1374-5792-4AEE-9A94-DCB70D1A9316

Q35093134-3D6CEB3A-B5A2-433E-B196-115EF30C4742

P304

Q35093134-D6933AB8-B4C4-43BC-9578-68F77EB14981

P31

Q35093134-D6A7299C-EF10-47E9-B83A-B1183EAA1C23

P356

Q35093134-25D4E308-DF2D-48AD-8224-E1A722E418FD

P433

Q35093134-26E5E30A-BEB4-41F8-8418-2401D4B1D92D

P478

Q35093134-98331D57-BB60-4DEF-8283-4697084591AF

P577

Q35093134-0987C92C-B625-420C-84D0-726152B2CF6B

P5875

Q35093134-115A7304-A8C0-432F-B149-8C136EA4FBD1

P698

Q35093134-89A2A691-5853-47FD-AADD-E7EF88E36E13

P932

Q35093134-C1C6708A-5FEA-4E68-AAE4-58BE4EDF5AAD

P356

J.1478-3231.2009.02156.X

P1433

Liver International

P1476

Hepatitis C treatment completion rates in routine clinical care.

@en

P2093

Adeel A Butt

http://www.w3.org/2001/XMLSchema#string

Amy C Justice

http://www.w3.org/2001/XMLSchema#string

Kathleen A McGinnis

http://www.w3.org/2001/XMLSchema#string

Melissa Skanderson

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Hepatitis C virus infection and the risk of coronary disease.

Rate and predictors of treatment prescription for hepatitis C.

Hepatitis C virus infection: the new global epidemic.

Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies.

P304

240-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1478-3231.2009.02156.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38066825

http://www.w3.org/2001/XMLSchema#string

P698

19889081

http://www.w3.org/2001/XMLSchema#string

P932

3132089

http://www.w3.org/2001/XMLSchema#string